InvestorsHub on MSN
Genentech’s Gazyva receives FDA priority review for primary membranous nephropathy
Genentech has received FDA Priority Review for Gazyva in primary membranous nephropathy, bringing the therapy closer to ...
Genentech will cut 103 jobs across several areas of the company at its South San Francisco headquarters, including its ...
Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...
– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New subcutaneous (SC ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...
SOUTH SAN FRANCISCO, Calif., July 02, 2026--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study ...
Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in breast cancerAstex to receive an upfront and potential ...
Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/precigen-sees-q1-revenue-exceeding-18m-consensus-20-8m ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s supplemental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results